Mr. Huang Hai joined Fosun Kite Biotechnology Co., Ltd. (FSK in short) as CEO in December 2020. Based on the combination of independent R&D and technology transfer, FSK is committed to the industrialization and standardization of tumor immune cell therapy technology (CAR-T/TCR-T) in China to benefit Chinese patients. Mr. Huang Hai has nearly 25 years of experience in commercial operations and international management in the pharmaceutical industry. He has worked in multinational pharmaceutical companies such as Pfizer, Sanofi, Roche Diagnostics and Medtronic. Prior to joining FSK, he served as the Chief Operating Officer (COO) of Upjohn China. In 2018, he created China’s first single product with annual sales of US$1.2 billion; and in the environment of mass procurement, he actively developed Upjohn’s future strategy and deployed Internet medical services.